A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.

Trial Details

NCT ID
NCT07604064
Phase
PHASE2
Sponsor
Kissei Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Olutasidenib
Locations (sample)
  • Tokyo and Other Japanese Cities, Japan

Key Eligibility Criteria

  • Japanese patients who personally provide written informed consent to participate in this clinical trial
  • Patients with a confirmed diagnosis of AML based on WHO classification (2022 edition) (except acute promyelocytic leukemia with t (15:17) transloca…
  • Patients with relapsed or refractory AML who may or may not have undergone allogeneic hematopoietic stem cell transplantation.
  • Patients with IDH1 gene mutation confirmed by central confirmation after relapse or refractoriness

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →